Reuters logo
BRIEF-Transgene announces phase 2 trial with Bristol-Myers Squibb for 2nd line treatment of metastatic non-small cell lung cancer
December 7, 2016 / 5:21 PM / a year ago

BRIEF-Transgene announces phase 2 trial with Bristol-Myers Squibb for 2nd line treatment of metastatic non-small cell lung cancer

Dec 7 (Reuters) - Transgene SA :

* Transgene: UC Davis to conduct phase 2 trial of the combination of TG4010 with Opdivo (nivolumab) for 2nd line treatment of metastatic non-small cell lung cancer (nsclc)

* This trial is supported by Transgene through financial support and supply of TG4010 and by Bristol-Myers Squibb through supply of nivolumab for use in clinical study Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below